(Updates with the latest stock movement in the first paragraph and headline.)
Krystal Biotech (KRYS) shares were down 8.2% in Monday trading after the company's Q2 product revenue fell short of analysts' estimate.
The company reported Q2 net income Monday of $1.79 per diluted share, compared with $1.29 a year earlier.
Three analysts surveyed by FactSet expected $1.62.
Net product revenue for the quarter ended June 30 was $119.2 million, compared with $96 million a year earlier.
Analysts expected $120.9 million.
Price: $313.00, Change: $-28.12, Percent Change: -8.24%